COVID-19-associated mucormycosis and treatments

In the current pandemic, COVID-19 patients with predisposing factors are at an increased risk of mucormycosis, an uncommon angioinvasive infection that is caused by fungi with Mucor genus which is mainly found in plants and soil. Mucormycosis development in COVID-19 patient is related to various fac...

Full description

Bibliographic Details
Published in:Asian Pacific Journal of Tropical Medicine
Main Authors: Vetriselvan Subramaniyan, Shivkanya Fuloria, Hari Kumar Darnal, Dhanalekshmi Unnikrishnan Meenakshi, Mahendran Sekar, Rusli Bin Nordin, Srikumar Chakravarthi, Kathiresan V Sathasivam, Shah Alam Khan, Yuan Seng Wu, Usha Kumari, Kalvatala Sudhakar, Rishabha Malviya, Vipin Kumar Sharma, Neeraj Kumar Fuloria
Format: Article in Journal/Newspaper
Language:English
Published: Wolters Kluwer Medknow Publications 2021
Subjects:
mucormycosis
covid-19
immunosuppression
pathogenesis
treatment
Arctic medicine. Tropical medicine
RC955-962
Arctic
Online Access:https://doi.org/10.4103/1995-7645.326253
https://doaj.org/article/96c9ab5b19b140478e50b3750ec04b1f
Description
Summary:In the current pandemic, COVID-19 patients with predisposing factors are at an increased risk of mucormycosis, an uncommon angioinvasive infection that is caused by fungi with Mucor genus which is mainly found in plants and soil. Mucormycosis development in COVID-19 patient is related to various factors, such as diabetes, immunocompromise and neutropenia. Excessive use of glucocorticoids for the treatment of critically ill COVID-19 patients also leads to opportunistic infections, such as pulmonary aspergillosis. COVID-19 patients with mucormycosis have a very high mortality rate. This review describes the pathogenesis and various treatment approaches for mucormycosis in COVID-19 patients, including medicinal plants, conventional therapies, adjunct and combination therapies.

Similar Items